Skip to Content
Stock Analyst Update

Archer-Daniels Midland Boosts Nutrition Footprint

While we are skeptical of the revenue synergies the firm hopes to achieve with its purchase of Neovia and Protexin, we think the cost savings synergies are largely achievable.


 Archer-Daniels Midland (ADM) announced two acquisitions in the company's nutrition business. It plans to acquire Neovia, a global animal nutrition company based in France, for nearly $1.8 billion (EUR 1.535 billion). It also plans to acquire Protexin, a human and animal nutrition company based in the U.K., for just over $240 million (GBP 185 million). Management expects both transactions to close by the end of the year. The deals will be financed with existing cash and short-term debt.

The Neovia acquisition price reflects an enterprise value to EBITDA multiple of around 14 times before synergies, which is in line with comparable transactions based on PitchBook data. The Protexin acquisition price reflects a 16 times multiple before synergies, which is slightly above the comparable transactions multiple.

Of management’s proposed synergies totaling $50 million, $35 million would come from cost savings and the remaining $15 million from revenue synergies. While we are skeptical of the revenue synergies, we think the cost savings synergies are largely achievable. Given Archer-Daniels' existing transportation infrastructure, we think the company will be able to realize cost savings synergies through the reduction of distribution expenses as well as the the elimination of some dual back office functions that include research and development and SG&A. After accounting for $35 million of synergies, we think the company negotiated a fair price for both acquisitions. As such, we maintain our $46 per share fair value estimate and no-moat rating.

Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.

Seth Goldstein does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.